NCT03702231View on ClinicalTrials.gov

Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's Tyrosine Kinase Inhibitor (BTK-I)

PHASE2CompletedINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

December 7, 2018

Primary Completion Date

September 9, 2020

Study Completion Date

July 12, 2023

Conditions
Safety and TolerabilityCompare SHINGRIX Vaccine Response RatesChronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)
Interventions
BIOLOGICAL

Zoster Vaccine Recombinant, Adjuvanted

A series of 2 doses of SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted) will be given on a 0- and 3-month schedule by intramuscular injection.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Heart, Lung, and Blood Institute (NHLBI)

NIH

NCT03702231 - Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's Tyrosine Kinase Inhibitor (BTK-I) | Biotech Hunter | Biotech Hunter